


SUPPLEMENTARY DATA

Supplementary Figure 1:


Protocol 1: Assessment of the effects of GLP-1 on vascular reactivity during hyperinsulinemia in MetS patients and in controls.



SUPPLEMENTARY DATA

Supplementary Figure 2:


Protocol 2: Assessment of the effects of GLP-1 on vascular reactivity of MetS patients in the Absence of Hyperinsulinemia.



SUPPLEMENTARY DATA

Supplementary Figure 3:


Protocol 3: Assessment of the effect of GLP-1 on vasodilator function during hyperinsulinemia and vitamin C infusion in Mets patients.



SUPPLEMENTARY DATA

Supplementary Figure 4:


Protocol 4: Assessment of the effects of the metabolite GLP-1(9-36) on vascular reactivity during hyperinsulinemia in MetS patients.



SUPPLEMENTARY DATA

Supplementary Figure 5:

Protocol 5. Assessment of the effects of GLP-1 on forearm glucose disposal during hyperinsulinemia in MetS patients.



SUPPLEMENTARY DATA

Supplementary Table 1. Clinical Characteristics of the Study Population

	<i>Controls</i>	<i>Metabolic Syndrome</i>	
	(n=5)	(n=25)	<i>P value</i>
<i>Sex (m/f)</i>	2/3	12/13	
<i>Age (years)</i>	45±3	46±2	0.54
<i>BMI (kg/m²)</i>	38±4	40±2	0.61
<i>Waist (cm)</i>	119±6	120±3	0.81
<i>Smoking (yes/no)</i>	4/1	21/4	0.84
<i>MAP (mmHg)</i>	97±2	106±2	0.01
<i>Total Cholesterol (mmol/L)</i>	4.87±0.10	5.31±0.21	0.24
<i>HDL Cholesterol (mmo/L)</i>	1.37±0.10	1.09±0.05	0.01
<i>Triglycerides (mmo/L)</i>	1.31±0.18	1.94±0.16	0.04
<i>Glucose (mmo/L)</i>	5.05±0.05	5.88±.22	0.07

Data are expressed as mean±SEM. BMI: body mass index; MAP: mean arterial pressure; HDL: high-density lipoprotein.

There was no significant difference in any of the variables among the 5 MetS groups.